Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Int J Cancer. 2016 Aug 18;139(11):2519–2528. doi: 10.1002/ijc.30372

Figure 2. Comparison of the 5-year OS, 3-year PFS and DFS rates in the uninfected controls, HCV-infected cases never given AVT, and HCV-infected cases given AVT before DLBCL diagnosis.

Figure 2

(A) Five-year OS rate. (B) Five-year OS rate including only patients achieving SVR. (C) Three-year PFS rate. (D) Three-year DFS rate.

AVT indicates antiviral therapy; DFS, disease free survival; HCV, hepatitis C virus; PFS, progression free survival; OS, overall survival; SVR, sustained virologic response.